FDA Questions Revlimid Dose, Toxicity And Single-Arm Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee will be asked whether Celgene’s single-arm study design is adequate to show clinical benefit in a heterogeneous disease like myelodysplastic syndromes.
You may also be interested in...
Celgene’s Revlimid Phase II Data Sufficient For Full Approval In MDS
FDA’s Oncologic Drugs Advisory Committee recommends full approval of Celgene’s Revlimid for myelodysplastic syndromes despite FDA concerns about trial design, dosing and toxicity.
Celgene’s Revlimid Phase II Data Sufficient For Full Approval In MDS
FDA’s Oncologic Drugs Advisory Committee recommends full approval of Celgene’s Revlimid for myelodysplastic syndromes despite FDA concerns about trial design, dosing and toxicity.
MGI/SuperGen’s Dacogen Is “Approvable” Pending Transfusion Data Analysis
Companies expect to submit requested data to FDA early in the fourth quarter for the myelodysplastic syndromes therapy.